Physician profile
William Wayne Cheatham
NPI 1639154198
$1,155.49
in general payments reported to CMS, 2019-2025
13 companies · $59.58 in 2025
The $59.58 reported for 2025 was less than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $35.15 · 2020: $133 · 2021: $77.17 · 2022: $327 · 2023: $303 · 2024: $221 · 2025: $59.58.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $583.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $583.39 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $488.13 | 2019-2024 | Wegovy, Rybelsus, Ozempic |
| Lilly USA, LLC | $195.77 | 2020-2024 | Mounjaro, Zepbound |
| Idorsia Pharmaceuticals US INC | $115.23 | 2022-2023 | Quviviq |
| Gilead Sciences, INC. | $92.89 | 2024-2025 | |
| Viiv Healthcare Company | $56.27 | 2024 | Apretude |
| Abbott Laboratories | $48.85 | 2021-2023 | Octrode |
| Exact Sciences Corporation | $37.32 | 2023 | Cologuard Collection Kit |
| Boehringer Ingelheim Pharmaceuticals, INC. | $26.50 | 2024 | |
| Boston Scientific Corporation | $25.08 | 2022 | |
| Neotract INC. | $20.68 | 2019 | |
| Glaxosmithkline, LLC. | $20.07 | 2022 | |
| Amgen INC. | $16.39 | 2024 | Repatha, Otezla |
| Cequr Corporation | $12.31 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw William Cheatham listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.